Organic Active Ingredients TRIZ Cases

Aloe vera gel, hyaluronic acid, and honey form a mucoadhesive film on the esophageal mucosa to reduce inflammation.

Oral dissolvable alginate film provides consistent naloxone plasma concentrations, resolving low bioavailability in needle-free overdose treatments.

Covalent geminal diamine bonds stabilize aptamer-toxin complexes against dissociation, ensuring selective cancer cell targeting and reduced systemic toxicity.

Separable polygonal patch segments in a backing layer allow precise lesion coverage without wasting adhesive.

Pyridinone dicarboxamide compounds selectively inhibit BD2 of BET proteins, resolving the trade-off between broad activity and specific therapeutic outcomes.

Combining conjugated linoleic acid with cyclopropenoid fatty acids converts harmful carcass fat effects into beneficial quality improvements.

Clofazimine synergizes with tyrosine kinase inhibitors to nearly obliterate quiescent leukemia stem cells that resist standard therapy.

Compound A targets EP4 receptors to treat chronic renal failure while minimizing side effects on other EP subtypes.

Water dispersible enalapril minitablets enable precise pediatric dosing through rapid disintegration and uniform suspension in liquid.

Thienopyridine compounds inhibit HIF prolyl hydroxylases, stabilizing HIF levels to treat ischemia and anemia.

Laminin receptor precursor mediates dopamine synthesis, reducing levodopa dosage and minimizing dyskinesia side effects.

A lithium hydroxide and carbon dioxide dissolution process preserves molecular weight and oxidation state, overcoming harsh traditional solvent degradation.

Blocking the CCL7/CCR3 axis prevents tumor spread outside the prostatic capsule.

Porous calcium carbonate reversibly absorbs nicotine to stabilize active ingredients and prevent unfavorable interactions between formulation components.

A cyclic amine derivative provides strong analgesic action through specific stereochemical configurations.

Verbascoside restores nephrin and synaptopodin expression in glomerular podocytes, reducing proteinuria by repairing cytoskeletal damage.

Drying morphine sulfate methanolic solvate in water vapor replaces methanol molecules, reducing genotoxic ABUK impurities below 25 ppm.

A 5'-hydroxy-5-nitro-indirubin-3'-oxime compound selectively inhibits cyclin-dependent kinases to arrest cancer cell cycles.

Segmenting film production into independent layers bonded by a water-soluble adhesive reduces drying time and prevents active ingredient stress.

Benzyl alcohol preserves oral melatonin solutions against microbial contamination while sodium ascorbate prevents oxidation, ensuring patient compliance.

Compounds form covalent bonds with cysteine residues to lock the switch II region into an inactive conformation.

Dimebolins modulate glutamate receptors and inhibit calcium channels to reduce seizure frequency while minimizing adverse effects.

Replacing sodium with meglumine prevents lyophilized mass formation, resolving the solubility-dissolution time contradiction.

Topical diacerein formulations bypass gastrointestinal metabolism to treat systemic conditions while avoiding laxative side effects.

A 6-chloro phenoxychroman carboxylic acid derivative acts as a specific DP2 receptor antagonist to inhibit allergic responses.

PEG-lipid nanoparticles encapsulate hydrophobic retinoids, bypassing efflux carriers and solubility limits to treat neurodegenerative diseases.

Combining adrenergic compounds with steroids reduces side effects and rebound congestion while maintaining effective nasal passage patency.

A benzoylamino acetic acid derivative resists tumor cell migration and invasion with low cytotoxicity.

An aromatic compound designed for estrogen receptor degradation.

GC-1 sobetirome accelerates hepatocyte proliferation to prevent post-hepatectomy liver failure and improve graft survival rates.

Synthetic compounds modulate intracellular NAD levels to protect healthy cells and target unhealthy tissues.

Myriocin nanocarriers inhibit de novo ceramide synthesis to reduce infarct size and improve cardiac contractility.

Chiral resolution isolates active enantiomers to reduce hypersensitivity and drug resistance in cardiac treatments.

Novel 2-oxo-5H-chromeno[4,3-b]pyridine compounds target viral replication and cccDNA production.

Phytoecdysones reduce lipid deposition while preserving muscle strength during low-calorie diets.

Aziridine prodrugs activate selectively in hypoxic tumor environments, reducing cancer cell viability while sparing normal tissues from damage.

Cell-penetrating peptides deliver CRISPR RNA to selectively cleave target bacterial DNA sequences.

RARβ agonists activate nuclear receptors to reduce oxidative stress and mast cell degranulation, preventing reperfusion injury and arrhythmias.

Recombinant adeno-associated viruses deliver short hairpin RNAs to target mutant SOD1 polynucleotides.

Injectable thermosensitive hydrogels deliver antibiotics to infected spinal sites via in situ gelation.

A nanoparticle vector enables targeted RNA self-delivery through host-guest interactions between cyclodextrin and adamantane ligands.

Simplified pyrano[2,3-c]xanthene compounds provide selective OSBP inhibition and stability while avoiding complex synthesis routes.

Calcium electroporation induces tumor necrosis via calcium overload, overcoming apoptosis resistance in cancer treatment.

Segmented gastro-resistant microspheres ensure homogeneous drug release in the colon, resolving incomplete distribution from conventional tablets.

Small molecule linkers couple cytotoxins to affibodies, creating nanoparticles that reduce systemic toxicity while maintaining high cytotoxicity at tumor sites.

Targeting alpha3 subunits avoids alpha1 activation, eliminating sedation and cognitive impairment while treating neuropathic pain.

Lactic acid bacterium exopolysaccharides increase CCR6-positive CD8+ T lymphocyte populations to improve cancer treatment efficacy.

Topical pea protein and polysaccharide combination restores skin barrier function by reducing tight junction alterations.

Chromenone inhibitors bind peripheral pockets on mutant PI3Kα, sparing wild-type enzyme activity and reducing metabolic toxicity.